Nuvectis Pharma Inc Cash Flow Conversion Efficiency
Nuvectis Pharma Inc cash flow conversion efficiency. Based on the latest financial reports, Nuvectis Pharma Inc (NVCT) has a cash flow conversion efficiency ratio of -0.499x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.53 Million) by net assets ($9.08 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Nuvectis Pharma Inc (2020–2025)
Cash flow conversion efficiency of Nuvectis Pharma Inc from 2020 to 2025. This chart illustrates how Nuvectis Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Nuvectis Pharma Inc stock quote for real-time trading data and today's change.
Nuvectis Pharma Inc Cash Flow Conversion Ratio Explained
Nuvectis Pharma Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Nuvectis Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nuvectis Pharma Inc ranked by their cash flow conversion efficiency. Also see NVCT market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Siantar Top Tbk
JK:STTP
|
0.042x |
|
Stingray Group Inc
TO:RAY-A
|
0.116x |
|
Shenzhen Yanmade Technology Inc
SHG:688312
|
0.022x |
|
Carasso
TA:CRSO
|
0.003x |
|
Science Environmental Protection Co. Ltd. A
SHG:688480
|
N/A |
|
Prashkovsky
TA:PRSK
|
0.061x |
|
Wereldhav B-Sicafi
BR:WEHB
|
0.032x |
|
Walton Advanced Engineering Inc
TW:8110
|
0.016x |
Annual Cash Flow Conversion Efficiency for Nuvectis Pharma Inc (2020–2025)
The table below shows the annual cash flow conversion efficiency of Nuvectis Pharma Inc from 2020 to 2025. Review Nuvectis Pharma Inc free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $18.41 Million | $-16.01 Million | -0.869x | +31.05% |
| 2024-12-31 | $9.71 Million | $-12.25 Million | -1.261x | +3.57% |
| 2023-12-31 | $12.20 Million | $-15.95 Million | -1.308x | -37.12% |
| 2022-12-31 | $14.22 Million | $-13.56 Million | -0.954x | -210.45% |
| 2021-12-31 | $-11.01 Million | $-9.50 Million | 0.863x | +23811.81% |
| 2020-12-31 | $6.65 Million | $24.00K | 0.004x | -- |
About Nuvectis Pharma Inc
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was forme… Read more